Tumor necrosis factor-α gene polymorphisms in age-related macular degeneration

Retina

Volumn 30, Issue 10, 2010, Pages 1595-1600

  Wan, Lei ^a,b   Lin, Hui Ju ^a   Tsai, Yushin ^b   Lee, Cheng Chun ^a   Tsai, Chang Hai ^a,c   Tsai, Fuu Jen ^a,c  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c ASIA UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RETINA MACULA AGE RELATED DEGENERATION; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; FEMALE; GENOTYPE; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; TAIWAN; TUMOR NECROSIS FACTOR-ALPHA; WET MACULAR DEGENERATION;

EID: 78649412027     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181dc58a6     Document Type: Article

References (39)

1. Bird AC. The Bowman Lecture. Towards an understanding of age-related macular disease. Eye 2003;17:457-466.
2. Congdon N, O'Colmain B, Klaver CC, et al; Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004;122:477-485. (Pubitemid 38456282)
3. Marx J. Genetics. A clearer view of macular degeneration. Science 2006;311:1704-1705.
4. Bird AC, Bressler NM, Bressler SB, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 1995; 39:367-374.
5. van Leeuwen R, Klaver CC, Vingerling JR, Hofman A, de Jong PT. The risk and natural course of age-related maculopathy: follow-up at 6 1/2 years in the Rotterdam study. Arch Ophthalmol 2003;121:519-526.
6. Chapman JA, Beckey C. Pegaptanib: a novel approach to ocular neovascularization. Ann Pharmacother 2006;40:1322-1326.
7. Fraunfelder FW. Pegaptanib for wet macular degeneration. Drugs Today (Bare) 2005;41:703-709.
8. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group; Chakravarthy U Ada-mis AP, Cunningham Jr. E.T., et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neo-vascular age-related macular degeneration. Ophthalmology 2006 113:1508.el-e25.
9. Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006;142:l-9.
10. Rosenfeld PJ, Heier JS, Hantsbarger G, Shams N. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lu-centis) for neovascular age-related macular degeneration. Ophthalmology 2006;l 13:623-632.
11. Theodossiadis PG, Liarakos VS, Sfikakis PP, Vergados IA, Theodossiadis GP. Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration. Am J Ophthalmol 2009;147: 825-830.
12. Oh H, Takagi H, Takagi C, et al. The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1999;40:1891-1898.
13. Armstrong D, Augustin AJ, Spengler R, et al. Detection of vascular endothelial growth factor and tumor necrosis factor alpha in epiretinal membranes of proliferative diabetic retinopathy, proliferative vitreoretinopathy and macular pucker. Ophthalmologica 1998;212:410-414.
14. Higuchi T, Seki N, Kamizono S, et al. Polymorphism of the 5#-flanking region of the human tumor necrosis factor (TNF)-a gene in Japanese. Tissue Antigens 1998;51:605-612.
15. Udalova IA, Richardson A, Denys A, et al. Functional consequences of a polymorphism affecting NF-kappaB p50-p50 binding to the TNF promoter region. Mol Cell Biol 2000; 20: 9113-9119.
16. Van Heel DA, Udalova IA, De Silva AP, et al. Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF (-kappa)B transcription factors. Hum Mol Genet 2002;11:1281-1289.
17. Bouma G, Crusius JB, Oudkerk Pool M, et al. Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Scand J Immunol 1996;43:456-463.
18. Louis E, Franchimont D, Piron A, et al. Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 1998;113:401-416.
19. Huizinga TW, Westendorp RG, Bollen EL, et al. TNF-alpha promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. J Neuro-immunol 1997;72:149-153.
20. van Krugten MV, Huizinga TW, Kaijzel EL, et al. Association of the TNF +489 polymorphism with susceptibility and ra-diographic damage in rheumatoid arthritis. Genes Immun 1999;1:91-96.
21. Zimmerman PA, Guderian RH, Nutman TB. A new TNFA promoter allele identified in South American Blacks. Immu-nogenetics 1996;44:485-486.
22. Skoog T, van't Hooft FM, Kallin B, et al. A common functional polymorphism (C-A substitution at position 863) in the promoter region of the tumour necrosis factor-alpha (TNF-alpha) gene associated with reduced circulating levels of TNF-alpha. Hum Mol Genet 1999;8:1443-1449.
23. Day CP, Grove J, Daly AK, Stewart MW, Avery PJ, Walker M. Tumour necrosis factor-alpha gene promoter polymorphism and decreased insulin resistance. Diabetologia 1998;41:430-434.
24. Richardson A, Sisay-Joof F, Ackerman H, et al. Nucleotide diversity of the TNF gene region in an African village. Genes Immun 2001;2:343-348.
25. Kaijzel EL, Bayley JP, van Krugten MV, et al. Allele-specific quantification of tumor necrosis factor alpha (TNF) transcription and the role of promoter polymorphisms in rheumatoid arthritis patients and healthy individuals. Genes Immun 2001;2:135-144.
26. D'Aiuto F, Parkar M, Brett PM, Ready D, Tonetti MS. Gene polymorphisms in proinflammatory cytokines are associated with systemic inflammation in patients with severe periodontal infections. Cytokine 2004;28:29-34.
27. Kamizono S, Yamada K, Seki N, et al. Susceptible locus for obese type 2 diabetes mellitus in the 5#-flanking region of the tumor necrosis factor-alpha gene. Tissue Antigens 2000;55:449-452.
28. Nedwin GE, Naylor SL, Sakaguchi AY, et al. Human lymphotoxin and tumor necrosis factor genes: structure, homology and chromosomal localization. Nucleic Acids Res 1985;13:6361-6373.
29. Majka S, McGuire PG, Das A. Regulation of matrix metallo-proteinase expression by tumor necrosis factor in a murine model of retinal neovascularization. Invest Ophthalmol Vis Sci 2002;43:260-266.
30. Ueda T, Ueda T, Fukuda S, et al. Lipid hydroperoxide-induced tumor necrosis factor (TNF)-alpha, vascular endothelial growth factor and neovascularization in the rabbit cornea: effect of TNF inhibition. Angiogenesis 1998;1:174-184. (Pubitemid 128514253)
31. Olson JL, Courtney RJ, Mandava N. Intravitreal infliximab and choroidal neovascularization in an animal model. Arch Ophthalmol 2007;125:1221-1224.
32. Shi X, Semkova I, Muther PS, Dell S, Kociok N, Joussen AM. Inhibition of TNF-alpha reduces laser-induced choroidal neovascularization. Exp Eye Res 2006;83:1325-1334.
33. Markomichelakis NN, Theodossiadis PG, Sfikakis PP. Regression of neovascular age-related macular degeneration following infliximab therapy. Am J Ophthalmol 2005;139:537-540.
34. Park K, Kim N, Nam J, Bang D, Lee ES. Association of TNFA promoter region haplotype in Behcet's disease. J Korean Med Sci 2006;21:596-601.
35. Akman A, Sallakci N, Coskun M, et al. TNF-alpha gene 1031 T/C polymorphism in Turkish patients with Behcet's disease. Br J Dermatol 2006;155:350-356.
36. Li N, Zhou Z, Liu X, et al. Association of tumour necrosis factor alpha (TNF-alpha) polymorphisms with Graves' disease: a meta-analysis. Clin Biochem 2008;41:881-886.
37. Kamizono S, Hiromatsu Y, Seki N, et al. A polymorphism of the 5# flanking region of tumour necrosis factor alpha gene is associated with thyroid-associated ophthal-mopathy in Japanese. Clin Endocrinol (Oxf) 2000;52:759-764.
38. de Jong PT. Age-related macular degeneration. N Engl J Med 2006;355:1474-1485.
39. Kesarwani P, Mandhani A, Mittal RD. Polymorphisms in tumor necrosis factor-A gene and prostate cancer risk in North Indian cohort. J Urol 2009;182:2938-2943.